Published in Nat Genet on January 27, 2013
Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature (2015) 5.50
Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science (2015) 3.29
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci U S A (2013) 2.49
Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov (2013) 2.49
Genomic and molecular characterization of esophageal squamous cell carcinoma. Nat Genet (2014) 2.02
Mutational landscape of gingivo-buccal oral squamous cell carcinoma reveals new recurrently-mutated genes and molecular subgroups. Nat Commun (2013) 1.62
NOTCH1 mutations occur early during cutaneous squamous cell carcinogenesis. J Invest Dermatol (2014) 1.40
Genomic analyses reveal mutational signatures and frequently altered genes in esophageal squamous cell carcinoma. Am J Hum Genet (2015) 1.28
A surprising cross-species conservation in the genomic landscape of mouse and human oral cancer identifies a transcriptional signature predicting metastatic disease. Clin Cancer Res (2014) 1.20
Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation. Leukemia (2013) 1.14
Squamous cell carcinoma of the oral tongue in young non-smokers is genomically similar to tumors in older smokers. Clin Cancer Res (2014) 1.13
The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies. Oncotarget (2014) 1.12
Shaping the nervous system: role of the core planar cell polarity genes. Nat Rev Neurosci (2013) 1.11
Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness. Blood (2014) 1.09
Mutational spectrum of adult T-ALL. Oncotarget (2015) 1.09
A synthetic lethal screen identifies FAT1 as an antagonist of caspase-8 in extrinsic apoptosis. EMBO J (2014) 1.01
The FAT epidemic: a gene family frequently mutated across multiple human cancer types. Cell Cycle (2013) 1.00
Key tumor suppressor genes inactivated by "greater promoter" methylation and somatic mutations in head and neck cancer. Epigenetics (2014) 0.98
Integrated mRNA and microRNA transcriptome sequencing characterizes sequence variants and mRNA-microRNA regulatory network in nasopharyngeal carcinoma model systems. FEBS Open Bio (2014) 0.93
WIF1 re-expression in glioblastoma inhibits migration through attenuation of non-canonical WNT signaling by downregulating the lncRNA MALAT1. Oncogene (2015) 0.89
Chemical Disruption of Wnt-dependent Cell Fate Decision-making Mechanisms in Cancer and Regenerative Medicine. Curr Med Chem (2015) 0.89
Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. Clin Cancer Res (2014) 0.88
Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse. Blood (2015) 0.86
Genetic Landscape of Human Papillomavirus-Associated Head and Neck Cancer and Comparison to Tobacco-Related Tumors. J Clin Oncol (2015) 0.86
Targeting β-catenin signaling for therapeutic intervention in MEN1-deficient pancreatic neuroendocrine tumours. Nat Commun (2014) 0.86
Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma. Proc Natl Acad Sci U S A (2016) 0.85
Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns. Oncotarget (2015) 0.85
Unraveling the molecular genetics of head and neck cancer through genome-wide approaches. Genes Dis (2014) 0.83
Inferring the progression of multifocal liver cancer from spatial and temporal genomic heterogeneity. Oncotarget (2016) 0.83
FAT4 functions as a tumour suppressor in gastric cancer by modulating Wnt/β-catenin signalling. Br J Cancer (2015) 0.81
FAT1 mutations cause a glomerulotubular nephropathy. Nat Commun (2016) 0.81
MAPK activation and HRAS mutation identified in pituitary spindle cell oncocytoma. Oncotarget (2016) 0.81
Precision medicine from the renal cancer genome. Nat Rev Nephrol (2016) 0.80
Control of mitochondrial function and cell growth by the atypical cadherin Fat1. Nature (2016) 0.80
Mutational landscape of adult ETP-ALL. Oncotarget (2013) 0.79
Genomic characterization of esophageal squamous cell carcinoma: Insights from next-generation sequencing. World J Gastroenterol (2016) 0.79
Molecular Aspects of Head and Neck Cancer Therapy. Hematol Oncol Clin North Am (2015) 0.77
Association between FAT1 mutation and overall survival in patients with human papillomavirus-negative head and neck squamous cell carcinoma. Head Neck (2016) 0.77
Cell biology: A mitochondrial brake on vascular repair. Nature (2016) 0.75
Synchronous Onset of Breast and Pancreatic Cancers: Results of Germline and Somatic Genetic Analysis. Case Rep Oncol (2016) 0.75
Genomic discoveries in adult astrocytoma. Curr Opin Genet Dev (2015) 0.75
CSN1 Somatic Mutations in Penile Squamous Cell Carcinoma. Cancer Res (2016) 0.75
Exome Sequencing of Oral Squamous Cell Carcinoma Reveals Molecular Subgroups and Novel Therapeutic Opportunities. Theranostics (2017) 0.75
FAT1 expression and mutations in adult acute lymphoblastic leukemia. Blood Cancer J (2014) 0.75
Genomic profiling reveals mutational landscape in parathyroid carcinomas. JCI Insight (2017) 0.75
Characterization of genetic aberrations in a single case of metastatic thymic adenocarcinoma. BMC Cancer (2017) 0.75
Chromosomal abnormalities and molecular landscape of metastasizing mucinous salivary adenocarcinoma. Oral Oncol (2017) 0.75
The tumor suppressor FAT1 modulates WNT activity in multiple cancers. Cancer Discov (2013) 0.75
FAT1: a potential target for monoclonal antibody therapy in colon cancer. Br J Cancer (2016) 0.75
Atypical Cadherin Fat1 Is Required for Lens Epithelial Cell Polarity and Proliferation but Not for Fiber Differentiation. Invest Ophthalmol Vis Sci (2015) 0.75
Whole-genome sequencing of spermatocytic tumors provides insights into the mutational processes operating in the male germline. PLoS One (2017) 0.75
The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas. Clin Cancer Res (2017) 0.75
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc (2009) 137.99
A method and server for predicting damaging missense mutations. Nat Methods (2010) 78.53
dbSNP: the NCBI database of genetic variation. Nucleic Acids Res (2001) 76.97
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
Consed: a graphical tool for sequence finishing. Genome Res (1998) 59.36
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Identifying biological themes within lists of genes with EASE. Genome Biol (2003) 31.72
Wnt/beta-catenin signaling in development and disease. Cell (2006) 30.09
Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science (1997) 24.61
Identification of c-MYC as a target of the APC pathway. Science (1998) 24.25
Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science (1997) 22.80
Wnt signalling in stem cells and cancer. Nature (2005) 19.26
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Functional interaction of beta-catenin with the transcription factor LEF-1. Nature (1996) 15.88
PolyPhred: automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencing. Nucleic Acids Res (1997) 13.48
XTcf-3 transcription factor mediates beta-catenin-induced axis formation in Xenopus embryos. Cell (1996) 11.70
Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer (2006) 11.22
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell (2005) 10.61
Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res (2008) 7.91
Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet (2004) 7.78
Morphogenetic roles of classic cadherins. Curr Opin Cell Biol (1995) 6.95
A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res (2006) 6.91
Comment on "The consensus coding sequences of human breast and colorectal cancers". Science (2007) 5.88
Hippo signaling: growth control and beyond. Development (2011) 5.25
Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. Hum Mol Genet (1992) 5.14
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res (2007) 4.99
Loss of Fat4 disrupts PCP signaling and oriented cell division and leads to cystic kidney disease. Nat Genet (2008) 4.28
E-cadherin suppresses cellular transformation by inhibiting beta-catenin signaling in an adhesion-independent manner. J Cell Biol (2001) 4.04
E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev (2009) 3.95
Beta-catenin mutations in cell lines established from human colorectal cancers. Proc Natl Acad Sci U S A (1997) 3.79
E-cadherin binding prevents beta-catenin nuclear localization and beta-catenin/LEF-1-mediated transactivation. J Cell Sci (1999) 3.55
Mutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating beta-catenin/TCF signalling. Nat Genet (2000) 3.33
An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells. Cancer Cell (2004) 3.30
YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway. Nat Cell Biol (2009) 3.26
Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res (2010) 3.24
The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol (2003) 3.06
The fat tumor suppressor gene in Drosophila encodes a novel member of the cadherin gene superfamily. Cell (1991) 3.00
U87MG decoded: the genomic sequence of a cytogenetically aberrant human cancer cell line. PLoS Genet (2010) 2.99
beta-Catenin signals regulate cell growth and the balance between progenitor cell expansion and differentiation in the nervous system. Dev Biol (2003) 2.85
Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. Cancer Res (2001) 2.78
Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer. Oncogene (2006) 2.69
PolyScan: an automatic indel and SNP detection approach to the analysis of human resequencing data. Genome Res (2007) 2.58
Inhibition of beta-catenin-mediated transactivation by cadherin derivatives. Proc Natl Acad Sci U S A (1998) 2.55
Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer. Cancer Res (2006) 2.47
Differential nuclear translocation and transactivation potential of beta-catenin and plakoglobin. J Cell Biol (1998) 2.38
Structure and transcription of a human gene for H1 RNA, the RNA component of human RNase P. Nucleic Acids Res (1990) 2.18
The Wnt antagonist sFRP1 in colorectal tumorigenesis. Cancer Res (2004) 2.16
Adhesion-independent mechanism for suppression of tumor cell invasion by E-cadherin. J Cell Biol (2003) 2.14
Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer. Br J Cancer (2008) 2.13
The xCELLigence system for real-time and label-free monitoring of cell viability. Methods Mol Biol (2011) 2.10
Oncogenic function of ATDC in pancreatic cancer through Wnt pathway activation and beta-catenin stabilization. Cancer Cell (2009) 2.04
Targeted inactivation of CTNNB1 reveals unexpected effects of beta-catenin mutation. Proc Natl Acad Sci U S A (2002) 1.94
ITF-2, a downstream target of the Wnt/TCF pathway, is activated in human cancers with beta-catenin defects and promotes neoplastic transformation. Cancer Cell (2002) 1.86
Frequent epigenetic inactivation of SFRP genes and constitutive activation of Wnt signaling in gastric cancer. Oncogene (2007) 1.81
Mice lacking the giant protocadherin mFAT1 exhibit renal slit junction abnormalities and a partially penetrant cyclopia and anophthalmia phenotype. Mol Cell Biol (2003) 1.76
Characterization of a Dchs1 mutant mouse reveals requirements for Dchs1-Fat4 signaling during mammalian development. Development (2011) 1.71
Mutations at the fat locus interfere with cell proliferation control and epithelial morphogenesis in Drosophila. Dev Biol (1988) 1.71
Involvement of claudin-1 in the beta-catenin/Tcf signaling pathway and its frequent upregulation in human colorectal cancers. Oncol Res (2001) 1.66
Molecular cloning and tissue expression of FAT, the human homologue of the Drosophila fat gene that is located on chromosome 4q34-q35 and encodes a putative adhesion molecule. Genomics (1995) 1.59
Scribble participates in Hippo signaling and is required for normal zebrafish pronephros development. Proc Natl Acad Sci U S A (2009) 1.57
Identification of Fat4 as a candidate tumor suppressor gene in breast cancers. Int J Cancer (2009) 1.49
Genomic mutation consequence calculator. Bioinformatics (2007) 1.48
Id2 is a target of the beta-catenin/T cell factor pathway in colon carcinoma. J Biol Chem (2001) 1.44
Mammalian Fat1 cadherin regulates actin dynamics and cell-cell contact. J Cell Biol (2004) 1.42
New insights into Fat cadherins. J Cell Sci (2005) 1.35
Regulation of endothelial barrier function and growth by VE-cadherin, plakoglobin, and beta-catenin. Am J Physiol Cell Physiol (2002) 1.26
No evidence for mutations in the alpha- and beta-catenin genes in human gastric and breast carcinomas. Cancer Res (1996) 1.26
The SFRP family of WNT inhibitors function as novel tumor suppressor genes epigenetically silenced in medulloblastoma. Oncogene (2010) 1.23
Expression of mouse dchs1, fjx1, and fat-j suggests conservation of the planar cell polarity pathway identified in Drosophila. Dev Dyn (2005) 1.21
Mammalian Fat and Dachsous cadherins regulate apical membrane organization in the embryonic cerebral cortex. J Cell Biol (2009) 1.19
Nuclear beta-catenin in basal cell carcinoma correlates with increased proliferation. Br J Dermatol (2004) 1.18
The Fat1 cadherin integrates vascular smooth muscle cell growth and migration signals. J Cell Biol (2006) 1.18
Functional interactions between Fat family cadherins in tissue morphogenesis and planar polarity. Development (2012) 1.17
Deletions in chromosome 4 differentially associated with the development of cervical cancer: evidence of slit2 as a candidate tumor suppressor gene. Hum Genet (2007) 1.16
Hippo signaling at a glance. J Cell Sci (2010) 1.14
Cadherin sequences that inhibit beta-catenin signaling: a study in yeast and mammalian cells. Mol Biol Cell (2001) 1.13
Identification of homozygous deletions of tumor suppressor gene FAT in oral cancer using CGH-array. Oncogene (2007) 1.07
The fat-like gene of Drosophila is the true orthologue of vertebrate fat cadherins and is involved in the formation of tubular organs. J Biol Chem (2004) 1.05
TGF-β synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth. J Exp Med (2012) 1.01
The comparison of impedance-based method of cell proliferation monitoring with commonly used metabolic-based techniques. Neuro Endocrinol Lett (2009) 1.00
Comparative integromics on FAT1, FAT2, FAT3 and FAT4. Int J Mol Med (2006) 0.94
Frequent silencing of a putative tumor suppressor gene melatonin receptor 1 A (MTNR1A) in oral squamous-cell carcinoma. Cancer Sci (2008) 0.93
Deletion of chromosome 4q predicts outcome in stage II colon cancer patients. Anal Cell Pathol (Amst) (2010) 0.91
Identification of MYCBP as a beta-catenin/LEF-1 target using DNA microarray analysis. Life Sci (2005) 0.88
Modulation of cell-cell adherens junctions by surface clustering of the N-cadherin cytoplasmic tail. Exp Cell Res (1998) 0.86
Frequent deletion of ING2 locus at 4q35.1 associates with advanced tumor stage in head and neck squamous cell carcinoma. J Cancer Res Clin Oncol (2008) 0.84
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A (2004) 33.85
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res (2006) 18.44
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med (2005) 15.42
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature (2012) 8.77
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature (2012) 8.66
IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature (2012) 7.95
Gene expression profiling of gliomas strongly predicts survival. Cancer Res (2004) 7.79
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med (2006) 7.10
Genome sequencing identifies a basis for everolimus sensitivity. Science (2012) 6.71
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med (2010) 5.57
Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med (2008) 5.54
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science (2013) 5.10
A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle. Nat Med (2012) 4.64
Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med (2006) 4.63
A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood (2002) 4.59
LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell (2013) 4.58
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med (2005) 4.44
Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol (2010) 4.23
PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res (2009) 3.95
Gene connectivity, function, and sequence conservation: predictions from modular yeast co-expression networks. BMC Genomics (2006) 3.87
Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res (2009) 3.56
Distinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Res (2006) 3.41
Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet (2007) 3.39
Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays. PLoS Comput Biol (2006) 3.39
Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res (2003) 3.36
Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res (2005) 3.35
Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stroma. Cell (2013) 3.33
Relationship of gene expression and chromosomal abnormalities in colorectal cancer. Cancer Res (2006) 3.32
Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res (2006) 3.31
Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res (2010) 3.24
Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol (2011) 3.23
Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients. J Natl Cancer Inst (2003) 3.15
Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest (2009) 3.14
Gene expression profiling identifies molecular subtypes of gliomas. Oncogene (2003) 3.13
A CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell (2006) 2.95
AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem (2003) 2.88
Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. Cancer Discov (2011) 2.77
Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat Biotechnol (2008) 2.75
Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol (2012) 2.74
Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell (2009) 2.73
MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol (2005) 2.70
CpG island methylator phenotype associates with low-degree chromosomal abnormalities in colorectal cancer. Clin Cancer Res (2008) 2.65
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov (2012) 2.61
Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol (2006) 2.58
High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. Arch Otolaryngol Head Neck Surg (2003) 2.56
Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology (2009) 2.55
The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proc Natl Acad Sci U S A (2009) 2.55
Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet (2009) 2.51
Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res (2008) 2.48
Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell (2007) 2.43
HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res (2011) 2.43
Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med (2005) 2.36
Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling. Clin Cancer Res (2003) 2.33
Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci Transl Med (2011) 2.33
Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma. Thyroid (2014) 2.31
Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Med Genomics (2008) 2.29
Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4. PLoS One (2007) 2.25
Glioblastoma: from molecular pathology to targeted treatment. Annu Rev Pathol (2013) 2.24
Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. J Nucl Med (2006) 2.24
EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci Signal (2009) 2.23
Primary glioblastomas express mesenchymal stem-like properties. Mol Cancer Res (2006) 2.18
Metabolic state of glioma stem cells and nontumorigenic cells. Proc Natl Acad Sci U S A (2011) 2.13
Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett (2006) 2.12
Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancer. Nucl Med Commun (2013) 2.12
Neurosphere formation is an independent predictor of clinical outcome in malignant glioma. Stem Cells (2009) 2.10
The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proc Natl Acad Sci U S A (2009) 2.09
Prospective functional voice assessment in patients undergoing thyroid surgery. Ann Surg (2002) 2.08
Primary mucosal malignant melanoma of the head and neck. Head Neck (2002) 2.07
PTEN dosage is essential for neurofibroma development and malignant transformation. Proc Natl Acad Sci U S A (2009) 2.07
Phase I/II study of resection and intraoperative cesium-131 radioisotope brachytherapy in patients with newly diagnosed brain metastases. J Neurosurg (2014) 2.03
Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget (2012) 2.03